ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53, and mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM)
Posted on: Jun 15, 2017 03:58PM
Lynparza Better Than Standard Chemotherapy for HER2-Negative Metastatic Breast Cancer in Women With BRCA Mutations
June 15, 2017
A study found that Lynparza improved progression-free survival by about 3 months in women diagnosed with metastatic, HER2-negative breast cancer who had a BRCA1 or BRCA2 mutation. Read more...